Merck’s efforts to combine its PD-1 blockbuster Keytruda with an experimental LAG-3 inhibitor hit a stumbling block Wednesday ...

Within the span of a week, the FDA gave the green light to another drug for the rare condition Niemann-Pick disease type C in ...

Genespire patched together a €46.6 million (about $52 million) funding round to get its lead gene therapy into the clinic in ...

Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma in patients with newly diagnosed multiple myeloma. 2seventy CEO Chip Baird ...

The FDA's Oncologic Drugs Advisory Committee will meet Thursday to discuss whether several immune checkpoint inhibitor drugs ...

Sen. Bernie Sanders (I-VT) told Novo Nordisk CEO Lars Fruergaard Jørgensen that three major pharmacy benefit managers have ...

Biotech company SIGA Technologies has fired Chief Medical Officer Jay Varma, days after the publication of secret recordings ...

Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with ...

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...

Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...

PCI Pharma Services is pouring $365 million to expand its US and Irish footprint for commercial and clinical packaging of ...

You win some, you lose some — that’s the risk of trying to predict the next hot biotechs. Since 2018, the Endpoints 11 awards ...